Study · Non-randomized trial · n = 10 · 2019
4 resultsXiao C, Stahel P, Morgantini C, Nahmias A, Dash S, Lewis GF
Diabetes, obesity & metabolism19 Aug 2019Cited by 17 (Europe PMC)
The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)
Text rights: Publisher copyright. Results still quote short attributed sentences.
4 results from studies that gave the peptide. 4 results from people.
In healthy male volunteers, teduglutide rapidly increased plasma triglyceride concentrations.
In plain wordsIn healthy men, teduglutide rapidly increased blood triglycerides.
n = 10
Source sentences
Teduglutide rapidly increased mesenteric blood flow and TG concentrations in plasma, in TG-rich lipoproteins, and most robustly in chylomicrons.
In healthy male volunteers, teduglutide rapidly increased triglycerides in TG-rich lipoproteins.
In plain wordsIn healthy men, teduglutide rapidly increased triglycerides in triglyceride-rich particles.
n = 10
Source sentences
Teduglutide rapidly increased mesenteric blood flow and TG concentrations in plasma, in TG-rich lipoproteins, and most robustly in chylomicrons.
In healthy male volunteers, teduglutide rapidly increased triglycerides most robustly in chylomicrons.
In plain wordsIn healthy men, teduglutide increased triglycerides most strongly in chylomicrons.
n = 10
Source sentences
Teduglutide rapidly increased mesenteric blood flow and TG concentrations in plasma, in TG-rich lipoproteins, and most robustly in chylomicrons.
In healthy male volunteers, teduglutide rapidly increased mesenteric blood flow.
In plain wordsIn healthy men, teduglutide rapidly increased blood flow to the intestine.
n = 6
Source sentences
Teduglutide rapidly increased mesenteric blood flow and TG concentrations in plasma, in TG-rich lipoproteins, and most robustly in chylomicrons.
TG in plasma and lipoprotein fractions were measured, along with measurement of blood flow in superior mesenteric and coeliac arteries using Doppler ultrasound in six participants.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC
Terms as the source lists them.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated